Cor Vasa 2016, 58(6):797-800

Hereditární plicní arteriální hypertenze - od farmakoterapie k transplantaci plic

Plicní arteriální hypertenze je vzácné a prognosticky závažné onemocnění. Incidence se uvádí v jednotkách na milion obyvatel a rok. Pro zlepšení prognózy nemocných je nutná včasná diagnóza a adekvátní léčba vedená v expertních centrech. Sdělení prezentuje kasuistické sdělení zaměřené na plicní arteriální hypertenzi manifestovanou v postpartálním období u mladé pacientky, diagnostický proces a léčbu - titraci kombinované terapie a směřování k provedení transplantace plic.



Abstract
Pulmonary arterial hypertension is a rare and prognostically serious disease, with a reported incidence of just > 1 per million inhabitants and year. A patient's prognosis can be substantially improved by timely diagnosis and adequate management in expert centers. The paper presents a case report of pulmonary arterial hypertension manifesting itself in the postpartum period of a young patient, the diagnostic algorithm and treatment involving titration of combination therapy and a bridge to lung transplantation.

Keywords: Combination therapy; Hereditary PAH; Lung transplantation; Postnatal period (postpartum); Pulmonary arterial hypertension; Treprostinil

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hereditární plicní arteriální hypertenze - od farmakoterapie k transplantaci plic. Cor Vasa. 2016;58(6):797-800.
Download citation

References

  1. M. Aschermann, P. Jansa, M. Hutyra, 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Summary document prepared by the Czech Society of Cardiology, Cor et Vasa 58 (2016) e129-e152. Go to original source...
  2. R.M. Tuder, S.L. Archer, P. Dorfmüller, et al., Relevant issues in the pathology and pathobiology of pulmonary hypertension, Journal of the American College of Cardiology 62 (25 Suppl) (2013) D4-D12. Go to original source... Go to PubMed...
  3. N. Galiè, M. Humbert, J.L. Vachiery, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal 37 (2016) 67-119. Go to original source... Go to PubMed...
  4. E. Demerouti, A. Manginas, S. Rammos, et al., Postpartum pulmonary arterial hypertension: two cases covering a wide spectrum of presentations, Hellenic Journal of Cardiology 53 (2012) 472-475.
  5. M.V. Martínez, J.D. Rutherford, Pulmonary hypertension in pregnancy, Cardiology in Review 21 (2013) 167-173. Go to original source... Go to PubMed...
  6. G. Simonneau, R.J. Barst, N. Galiè, et al., Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial, American Journal of Respiratory and Critical Care Medicine 165 (2002) 800-804. Go to original source... Go to PubMed...
  7. R. Sadushi-Koliçi, N. Skoro-Sajer, D. Zimmer, et al., Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension, Journal of Heart and Lung Transplantation 31 (2012) 735-743. Go to original source... Go to PubMed...
  8. M. Humbert, Z. Deng, G. Simonneau, et al., BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives, European Respiratory Journal 20 (2002) 518-523. Go to original source... Go to PubMed...
  9. F. Soubrier, W.K. Chung, R. Machado, et al., Genetics and genomics of pulmonary arterial hypertension, Journal of American College of Cardiology 62 (25 Suppl) (2013) D13-D21. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.